V

Viking Therapeutics
D

VKTX

40.030
USD
-0.23
(-0.57%)
مغلق
حجم التداول
174,488
الربح لكل سهم
-2
العائد الربحي
-
P/E
-26
حجم السوق
4,501,171,789
أصول ذات صلة
A
ABUS
-0.00500
(-0.15%)
3.36000 USD
ALNY
ALNY
6.65
(1.50%)
449.19 USD
A
ARWR
1.730
(9.21%)
20.510 USD
C
CRBP
-0.26000
(-2.72%)
9.31000 USD
MRNA
MRNA
1.330
(4.98%)
28.020 USD
V
VKTX
-0.230
(-0.57%)
40.030 USD
المزيد
الأخبار المقالات

العنوان: Viking Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.